首页 > 专栏 > The Lancet The Lancet 共 217 条资讯 [Comment] Faster troponin, same time in the emergency department: what is next for acute coronary syndrome assessment? 2026-06-28 11:43:09 [Articles] Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials 2026-06-28 11:43:09 [Review] Irritable bowel syndrome and related disorders of gut–brain interaction 2026-06-28 11:43:09 [Editorial] Health and poverty: lessons from China 2026-06-28 11:43:09 [Comment] Beyond poverty eradication: what China's health and poverty alleviation experience means for global health 2026-06-28 11:43:09 [The Lancet Commissions] A Lancet Commission on the Health and Poverty Alleviation Initiative in China 2026-06-28 11:43:09 [Comment] Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability? 2026-06-28 11:43:09 [Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China 2026-06-28 11:43:09 [Articles] Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial 2026-06-28 11:43:09 [Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-la 2026-06-28 11:43:09 [Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial 2026-06-28 11:43:09 [Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, ac 2026-06-28 11:43:09 [Correspondence] Super El Niño threatens a public health emergency in Africa 2026-06-28 11:43:09 [Countdown] The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all 2026-06-28 11:43:09 [Comment] Optimising late-line treatment administration in metastatic colorectal cancer: an even brighter SUNLIGHT 2026-06-28 11:43:09 [Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan 2026-06-28 11:43:09 [Articles] Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials 2026-06-28 11:43:09 [Comment] Preserving the uterus: an effective dual therapy to avoid hysterectomy 2026-06-28 11:43:09 [Articles] Endometrial ablation plus levonorgestrel-releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding in The Netherlands (MIRA2): a multicentre, open-label, randomised, controlled, superiority trial 2026-06-28 11:43:09 [Comment] Redefining curative treatment for early-stage mismatch repair-deficient colon cancer 2026-06-28 11:43:09 123…11下一页 » 相关分类 The Lancet ScienceDirect Publication: The Lancet ScienceDirect Publication: The Lancet Oncology The Lancet Child & Adolescent Health The Lancet Diabetes & Endocrinology The Lancet Digital Health The Lancet Gastroenterology & Hepatology The Lancet Global Health The Lancet HIV The Lancet Haematology The Lancet Healthy Longevity The Lancet Infectious Diseases The Lancet Microbe The Lancet Neurology The Lancet Oncology The Lancet Planetary Health The Lancet Psychiatry